Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell ...
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the completion of enrollment in NT-002, its Phase 1b clinical …